Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition |
On May 03, 2017, Clovis Oncology, Inc. (the Company) issued a
press release announcing its financial results for the quarter
ended March 31, 2016. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 of Form 8-K and the information
incorporated by reference herein, including Exhibit 99.1 attached
hereto, shall not be deemed to be filed for purposes of Section
18 of the Securities Exchange Act of 1934 (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Number and Description
| 99.1 | Press Release, dated May 03, 2017. |
About Clovis Oncology, Inc. (NASDAQ:CLVS)
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b). Clovis Oncology, Inc. (NASDAQ:CLVS) Recent Trading Information
Clovis Oncology, Inc. (NASDAQ:CLVS) closed its last trading session down -2.02 at 53.30 with 1,617,212 shares trading hands.
